Bioceltix (BCX) investor relations material

Executive summary

• Advanced regulatory, clinical, and investment milestones achieved, including submission of responses to EMA for BCX-CM-J and progress on other key products.

• Secured significant public funding for R&D and infrastructure, including a 15.1 mln PLN grant for InnoBioVet.

• Construction of a new manufacturing facility advanced, with permits and contracts in place.

• Maintained strong liquidity with 56.8 mln PLN in cash at period end.

Financial highlights

• No revenue generated in H1 2026, consistent with pre-commercialization stage.

• Net loss of 10.8 mln PLN, up from 7.4 mln PLN year-over-year, reflecting increased R&D and investment activity.

• Operating cash outflow of 8.7 mln PLN and total negative cash flow of 11.6 mln PLN.

• Equity at 62.5 mln PLN, liabilities and provisions at 3.2 mln PLN.

• Book value per share at 11.30 PLN.

Outlook and guidance

• Focus on completing additional analytical and validation work for BCX-CM-J, with EMA response deadline set for May 18, 2027.

• Continued development of BCX-EM and BCX-CM-AD, with regulatory submissions and clinical data supporting future commercialization.

• Ongoing investment in production capacity and preparation for commercialization.